Össur hf. - Total number of voting rights and capital

Registration of the capital increase of 29,500,000 shares completed

Not for release, publication,  or distribution in Australia,  Canada,
Japan or the United States.


                                         Press release from Össur hf.
                                Reykjavik, 6 November 2009; GMT 11:15


 Registration of the capital increase of 29,500,000 shares completed


We refer to the stock exchange announcement of 3 November 2009.

Össur hf.  is pleased  to announce  that the  capital increase  of  a
nominal value of ISK 29,500,000 (29,500,000 shares of a nominal value
of ISK 1 each) in connection with the private placement is completed.
The capital increase  today has  been registered  with the  Icelandic
Register   of   Enterprises.   The   capital   increase    represents
approximately  7.0%  of  the  share  capital  prior  to  the  capital
increase, and 6.5%  after the increase.  After the capital  increase,
the share capital  of Össur is  452,500,000 shares of  nominal ISK  1
each, equivalent to a nominal value of ISK 452,500,000.

The  new  shares  will  be  listed  under  the  existing  ISIN   code
IS0000000040 for the existing shares on NASDAQ OMX Iceland and NASDAQ
OMX Copenhagen with effect from 9 November 2009.
Further   information   can    be   found    on   Össur's    website:
www.ossur.com/investors.

Össur contacts:
Jon Sigurdsson, President & CEO, Tel: +354 515-1300
Hjorleifur Palsson, CFO, Tel: +354 515-1300
Sigurborg Arnarsdottir, IR Manager, Tel: +354 664-1044

Össur (OMX: OSSR)  is a  global leader  in non-invasive  orthopaedics
that help people  live a  life without limitations.  Its business  is
focused on  improving  people's  mobility  through  the  delivery  of
innovative technologies  within  the  fields  of  bracing,  supports,
prosthetic limbs and compression therapies. A recognized  "Technology
Pioneer",  Össur  invests  significantly  in  research  and   product
development; its award-winning designs ensuring a consistently strong
position in the market. Successful patient and clinical outcomes  are
further empowered  via  Össur's  educational  programs  and  business
solutions. Headquartered in  Iceland, Össur has  major operations  in
the  Americas,  Europe   and  Asia,   with  additional   distributors
worldwide.

*****

This announcement  is not  an offer  for sale  of securities  in  the
United States. Securities may  not be offered or  sold in the  United
States absent registration  or an exemption  from registration  under
the US  Securities  Act  of  1933  as  amended.  The  issuer  of  the
securities has not registered, and  does not intend to register,  any
portion of the offering in the United States, and does not intend  to
conduct a public offering of securities in the United States.
This announcement is only being  distributed to and is only  directed
at (i) persons who  are outside the United  Kingdom or (ii) that  are
qualified  investors  within  the  meaning  of  Article  2(1)(e)   of
Directive 2003/71/EC ("Prospectus Directive") and that are either (x)
investment  professionals  falling  within   Article  19(5)  of   the
Financial Services and Markets  Act 2000 (Financial Promotion)  Order
205 (the "Order") or (y) high net worth companies, and other  persons
to whom  it  may lawfully  be  communicated, falling  within  Article
49(2)(a) to (d) of the Order (all such persons in (i) and (ii)  above
together being referred to as "relevant persons"). The New Shares are
only  available  to,  and  any  invitation,  offer  or  agreement  to
subscribe, purchase  or otherwise  acquire  such securities  will  be
engaged in  only with,  relevant persons.  Any person  who is  not  a
relevant person should not act or rely on this document or any of its
contents.
This announcement is an advertisement and is not a prospectus for the
purposes of the Prospective  Directive, together with any  applicable
implementing measures in  the relevant  home Member  State under  the
Prospectus Directive.
In  any  EEA  Member  State  that  has  implemented  the  Prospective
Directive this  communication  is  only  addressed  to  and  is  only
directed at  qualified  investors in  that  Member State  within  the
meaning of the Prospectus Directive.

*****

This  announcement  contains   certain  forward-looking   statements,
including statements about the  Company's business and the  Offering.
Such forward-looking statements  are based on  data, assumptions  and
estimates that  the  Company considers  to  be reasonable.  They  may
change or be amended owing to uncertainties related to the  economic,
financial,  competitive  and   regulatory  environment,  and   market
conditions. In addition,  the Company's business  activities and  its
ability to meet its goals may be adversely affected if one or more of
the risks  that  are set  forth  in  the summary  document  that  was
prepared in connection with the listing of shares in Össur on  NASDAQ
OMX Copenhagen  in addition  to  the section  "Risk factors"  in  the
Company's  Annual  Report  2008  materialise,  or  if  other   risks,
currently unforeseen or  considered insignificant, materialise.   The
Company does not undertake to meet or give any guarantee that it will
meet its  goals. Investors  are urged  in particular  to pay  careful
attention to the risk factors described in the summary doucment  that
was prepared in  connection with the  listing of shares  in Össur  on
NASDAQ OMX Copenhagen in  addition to the  section "Risk factors"  in
the Company's Annual Report 2008.